Answers are grounded in this paper and cite their sources.
Type 2 diabetes mellitus (T2DM) has become a major global public health burden, and existing drugs cannot reverse the progressive failure of pancreatic β-cell function. Mesenchymal stem cells (MSCs), by virtue of their immunomodulatory, anti-inflammatory, and tissue-repair properties, offer a new strategy for the causal treatment of T2DM. This article reviews the development history and mechanisms of action of MSC therapy for T2DM, including restoration of insulin-resistance signaling pathways, reversal of β-cell dedifferentiation, suppression of chronic low-grade inflammation, and exosome-mediated paracrine effects; summarizes evidence from preclinical animal studies and recent representative clinical studies, analyzing safety and efficacy; and discusses translational bottlenecks such as cellular heterogeneity, low homing efficiency, and the lack of standardization, together with countermeasures including genetic modification, patient stratification, and exosome engineering. Current evidence indicates that MSC therapy for T2DM is safe and feasible, with glucose-lowering and organ-protective potential; however, complete remission rates are low and therapeutic responses are highly heterogeneous, and routine clinical application still requires high-quality evidence-based support and standardized systems.
No takes yet. Share an insight, caveat, or question.
Haotian Yang (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: